About this Journal Submit a Manuscript Table of Contents
International Journal of Endocrinology
Volume 2012 (2012), Article ID 561018, 16 pages
http://dx.doi.org/10.1155/2012/561018
Review Article

Mechanisms of Action of Topical Corticosteroids in Psoriasis

Clínica Universitária de Dermatologia, Faculdade de Medicina de Lisboa, Av. Professor Egas Moniz, 1649-035 Lisbon, Portugal

Received 31 August 2012; Revised 14 October 2012; Accepted 20 October 2012

Academic Editor: Egle Solito

Copyright © 2012 Luís Uva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Saraceno, T. Gramiccia, P. Frascione, and S. Chimenti, “Calcipotriene/betamethasone in the treatment of psoriasis: a review article,” Expert Opinion on Pharmacotherapy, vol. 10, no. 14, pp. 2357–2365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Lowes, A. M. Bowcock, and J. G. Krueger, “Pathogenesis and therapy of psoriasis,” Nature, vol. 445, no. 7130, pp. 866–873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. M. Laws and H. S. Young, “Topical treatment of psoriasis,” Expert Opinion on Pharmacotherapy, vol. 11, no. 12, pp. 1999–2009, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Henseler and E. Christophers, “Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris,” Journal of the American Academy of Dermatology, vol. 13, no. 3, pp. 450–456, 1985. View at Scopus
  5. M. Lebwohl, “Psoriasis,” The Lancet, vol. 361, no. 9364, pp. 1197–1204, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Menter, N. J. Korman, C. A. Elmets et al., “Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies,” Journal of the American Academy of Dermatology, vol. 60, no. 4, pp. 643–659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Murphy and K. Reich, “In touch with psoriasis: topical treatments and current guidelines,” Journal of the European Academy of Dermatology and Venereology, vol. 25, Supplement 4, pp. 3–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Reich and A. Bewley, “What is new in topical therapy for psoriasis?” Journal of the European Academy of Dermatology and Venereology, vol. 25, Supplement 4, pp. 15–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Castela, E. Archier, S. Devaux, et al., “Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities,” Journal of the European Academy of Dermatology and Venereology, vol. 26, Supplement 3, pp. 36–46, 2012.
  10. P. Van De Kerkhof, K. Kragballe, S. Segaert, and M. Lebwohl, “Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 10, pp. 1130–1139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. E. J. Horn, S. Domm, H. I. Katz, M. Lebwohl, U. Mrowietz, and K. Kragballe, “Topical corticosteroids in psoriasis: strategies for improving safety,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 2, pp. 119–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Schoepe, H. Schäcke, E. May, and K. Asadullah, “Glucocorticoid therapy-induced skin atrophy,” Experimental Dermatology, vol. 15, no. 6, pp. 406–420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. E. M. Sternberg, “Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens,” Nature Reviews Immunology, vol. 6, no. 4, pp. 318–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. D. Ference and A. R. Last, “Choosing topical corticosteroids,” American Family Physician, vol. 79, no. 2, pp. 135–140, 2009. View at Scopus
  15. P. J. Barnes, “Anti-inflammatory actions of glucocorticoids: molecular mechanisms,” Clinical Science, vol. 94, no. 6, pp. 557–572, 1998. View at Scopus
  16. T. Bhutani, J. Koo, and H. I. Maibach, “Efficacy of clobetasol spray: factors beyond patient compliance,” Journal of Dermatological Treatment, vol. 23, no. 1, pp. 11–15, 2012.
  17. R. C. Cornell and R. B. Stoughton, “Correlation of the vasoconstriction assay and clinical activity in psoriasis,” Archives of Dermatology, vol. 121, no. 1, pp. 63–67, 1985. View at Scopus
  18. S. R. Feldman and B. A. Yentzer, “Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations,” American Journal of Clinical Dermatology, vol. 10, no. 6, pp. 397–406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Lebwohl, P. T. Ting, and J. Y. M. Koo, “Psoriasis treatment: traditional therapy,” Annals of the Rheumatic Diseases, vol. 64, Supplement 2, pp. ii83–ii86, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Menter and C. E. Griffiths, “Current and future management of psoriasis,” The Lancet, vol. 370, no. 9583, pp. 272–284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Nast, I. B. Kopp, M. Augustin, et al., “Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 5, Supplement 3, pp. 1–119, 2007.
  22. A. Nast, I. Kopp, M. Augustin et al., “German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version),” Archives of Dermatological Research, vol. 299, no. 3, pp. 111–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. S. Chan, A. S. Van Voorhees, M. G. Lebwohl et al., “Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation,” Journal of the American Academy of Dermatology, vol. 60, no. 6, pp. 962–971, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. J. M. Van der Vleuten and P. C. M. Van de Kerkhof, “Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment,” Drugs, vol. 61, no. 11, pp. 1593–1598, 2001. View at Scopus
  25. J. Del Rosso and S. F. Friedlander, “Corticosteroids: options in the era of steroid-sparing therapy,” Journal of the American Academy of Dermatology, vol. 53, Supplement 1, pp. S50–S58, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. B. S. McKenzie, R. A. Kastelein, and D. J. Cua, “Understanding the IL-23-IL-17 immune pathway,” Trends in Immunology, vol. 27, no. 1, pp. 17–23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. P. Raychaudhuri, “Role of IL-17 in psoriasis and psoriatic arthritis,” Clinical Reviews in Allergy and Immunology. In press.
  28. R. McManus, “Mechanisms of steroid action and resistance in inflammation and disease,” Journal of Endocrinology, vol. 178, no. 1, pp. 1–4, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. P. B. Hebbar and T. K. Archer, “Chromatin remodeling by nuclear receptors,” Chromosoma, vol. 111, no. 8, pp. 495–504, 2003. View at Scopus
  30. L. I. McKay and J. A. Cidlowski, “Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways,” Endocrine Reviews, vol. 20, no. 4, pp. 435–459, 1999. View at Scopus
  31. K. De Bosscher, W. V. Berghe, and G. Haegeman, “The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression,” Endocrine Reviews, vol. 24, no. 4, pp. 488–522, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Rhen and J. A. Cidlowski, “Antiinflammatory action of glucocorticoids—new mechanisms for old drugs,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1711–1658, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Hafezi-Moghadam, T. Simoncini, Z. Yang et al., “Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase,” Nature Medicine, vol. 8, no. 5, pp. 473–479, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. A. C. Cato, A. Nestl, and S. Mink, “Rapid actions of steroid receptors in cellular signaling pathways,” Science's STKE, vol. 2002, no. 138, p. RE9, 2002. View at Scopus
  35. N. Z. Lu and J. A. Cidlowski, “The origin and functions of multiple human glucocorticoid receptor isoforms,” Annals of the New York Academy of Sciences, vol. 1024, pp. 102–123, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Pujols, J. Mullol, M. Pérez et al., “Expression of the human glucocorticoid receptor α and β isoforms in human respiratory epithelial cells and their regulation by dexamethasone,” American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 1, pp. 49–57, 2001. View at Scopus
  37. A. Ahluwalia, “Topical glucocorticoids and the skin-mechanisms of action: an update,” Mediators of Inflammation, vol. 7, no. 3, pp. 183–193, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Solito, C. De Coupade, L. Parente, R. J. Flower, and F. Russo-Marie, “IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein,” Cytokine, vol. 10, no. 7, pp. 514–521, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Mizuno, K. Uemura, A. Moriyama et al., “Glucocorticoid induced the expression of mRNA and the secretion of lipocortin 1 in rat astrocytoma cells,” Brain Research, vol. 746, no. 1-2, pp. 256–264, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Antonicelli, C. De Coupade, F. Russo-Marie, and Y. Le Garrec, “CREB is involved in mouse annexin A1 regulation by cAMP and glucocorticoids,” European Journal of Biochemistry, vol. 268, no. 1, pp. 62–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. S. W. Kim, H. J. Rhee, J. Ko et al., “Inhibition of cytosolic phospholipase A2 by annexin I: specific interaction model and mapping of the interaction site,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 15712–15719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. F. D'Acquisto, M. Perretti, and R. J. Flower, “Annexin-A1: a pivotal regulator of the innate and adaptive immune systems,” British Journal of Pharmacology, vol. 155, no. 2, pp. 152–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Perretti and F. D'Acquisto, “Annexin A1 and glucocorticoids as effectors of the resolution of inflammation,” Nature Reviews Immunology, vol. 9, no. 1, pp. 62–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. I. M. Adcock and G. Caramori, “Cross-talk between pro-inflammatory transcription factors and glucocorticoids,” Immunology and Cell Biology, vol. 79, no. 4, pp. 376–384, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Schäfer-Korting, B. Kleuser, M. Ahmed, H. D. Höltje, and H. C. Korting, “Glucocorticoids for human skin: new aspects of the mechanism of action,” Skin Pharmacology and Physiology, vol. 18, no. 3, pp. 103–114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Tanabe and N. Tohnai, “Cyclooxygenase isozymes and their gene structures and expression,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 95–114, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. H. M. Reichardt, J. P. Tuckermann, M. Göttlicher et al., “Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor,” EMBO Journal, vol. 20, no. 24, pp. 7168–7173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. P. C. Goldsmith, T. A. Leslie, N. A. Hayes, N. J. Levell, P. M. Dowd, and J. C. Foreman, “Inhibitors of nitric oxide synthase in human skin,” Journal of Investigative Dermatology, vol. 106, no. 1, pp. 113–118, 1996. View at Scopus
  49. R. M. Lavker and N. M. Schechter, “Cutaneous mast cell depletion results from topical corticosteroid usage,” Journal of Immunology, vol. 135, no. 4, pp. 2368–2373, 1985. View at Scopus
  50. H. I. Maibach and C. Surber, Topical Corticosteroids, Karger, New York, NY, USA, 1992.
  51. H. Schäcke, W. D. Döcke, and K. Asadullah, “Mechanisms involved in the side effects of glucocorticoids,” Pharmacology and Therapeutics, vol. 96, no. 1, pp. 23–43, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. D. B. Robertson and H. I. Maibach, “Topical corticosteroids,” International Journal of Dermatology, vol. 21, no. 2, pp. 59–67, 1982. View at Scopus
  53. N. Mygind and R. Dahl, “The rationale for use of topical corticosteroids in allergic rhinitis,” Clinical and Experimental Allergy, vol. 26, Supplement 3, pp. 2–10, 1996. View at Scopus
  54. S. Kloehn, T. Arendt, A. Reinecke-Lüthge, H. J. Klomp, and H. Mönig, “Cushing syndrome with life-threatening infectious complications,” Deutsche Medizinische Wochenschrift, vol. 122, no. 50, pp. 1547–1552, 1997. View at Scopus
  55. R. L. Black, R. B. Oglesby, L. Von Sallmann, and J. J. Bunim, “Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis,” JAMA, vol. 174, pp. 166–171, 1960. View at Scopus
  56. M. F. Armaly, “Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye,” Archives of Ophthalmology, vol. 70, pp. 482–491, 1963.
  57. R. Sayegh, S. D. Auerbach, X. Li et al., “Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5′-flanking region of the human epithelial sodium channel α subunit gene,” Journal of Biological Chemistry, vol. 274, no. 18, pp. 12431–12437, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. D. E. Sholter and P. W. Armstrong, “Adverse effects of corticosteroids on the cardiovascular system,” Canadian Journal of Cardiology, vol. 16, no. 4, pp. 505–511, 2000. View at Scopus
  59. T. M. Sartori, P. G. Maurizio, P. Sara et al., “Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation,” Journal of Heart and Lung Transplantation, vol. 18, no. 7, pp. 693–700, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Wu, D. Mills, and M. Bala, “Psoriasis: cardiovascular risk factors and other disease comorbidities,” Journal of Drugs in Dermatology, vol. 7, no. 4, pp. 373–377, 2008. View at Scopus
  61. I. Yoshiuchi, R. Shingu, H. Nakajima et al., “Mutation/polymorphism scanning of glucose-6-phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 3, pp. 1016–1019, 1998. View at Publisher · View at Google Scholar · View at Scopus
  62. B. Goichot, C. Wicky, F. Grunenberger, and J. L. Schlienger, “Hypothalamo-pituitary-adrenocortical function during and after steroid therapy: recent data and critical review,” Annales d'Endocrinologie, vol. 61, no. 5, pp. 452–458, 2000. View at Scopus
  63. N. E. Lane and B. Lukert, “The science and therapy of glucocorticoid-induced bone loss,” Endocrinology and Metabolism Clinics of North America, vol. 27, no. 2, pp. 465–483, 1998. View at Publisher · View at Google Scholar · View at Scopus
  64. S. R. Price, J. Du, J. L. Bailey, and W. E. Mitch, “Molecular mechanisms regulating protein turnover in muscle,” American Journal of Kidney Diseases, vol. 37, Supplement 2, pp. S112–S114, 2001. View at Scopus
  65. E. S. Brown, D. A. Khan, and V. A. Nejtek, “The psychiatric side effects of corticosteroids,” Annals of Allergy, Asthma and Immunology, vol. 83, no. 6, Part 1, pp. 495–504, 1999. View at Scopus
  66. A. Oikarinen and P. Autio, “New aspects of the mechanism of corticosteroid-induced dermal atrophy,” Clinical and Experimental Dermatology, vol. 16, no. 6, pp. 416–419, 1991. View at Scopus
  67. L. Kolbe, A. M. Kligman, V. Schreiner, and T. Stoudemayer, “Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin,” Skin Research and Technology, vol. 7, no. 2, pp. 73–77, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Pérez, A. Page, A. Bravo et al., “Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor,” The FASEB Journal, vol. 15, no. 11, pp. 2030–2032, 2001. View at Scopus
  69. S. J. Chen, W. Yuan, S. Lo, et al., “Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta,” Journal of Cellular Physiology, vol. 183, no. 3, pp. 381–392, 2000.
  70. C. Z. Song, X. Tian, and T. D. Gelehrter, “Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 21, pp. 11776–11781, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. B. C. Willis, J. M. Liebler, K. Luby-Phelps et al., “Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis,” American Journal of Pathology, vol. 166, no. 5, pp. 1321–1332, 2005. View at Scopus
  72. J. Câmara and G. Jarai, “Epithelial-mesenchymal transition in primary human bronchial epithelial cells is Smad-dependent and enhanced by fibronectin and TNF-α,” Fibrogenesis and Tissue Repair, vol. 3, no. 1, article 2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. V. Arnoux, M. Nassour, A. L'Helgoualc'h, R. A. Hipskind, and P. Savagner, “Erk5 controls slug expression and keratinocyte activation during wound healing,” Molecular Biology of the Cell, vol. 19, no. 11, pp. 4738–4749, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Oishi, Z. W. Fu, Y. Ohnuki, H. Kato, and T. Noguchi, “Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases,” British Journal of Dermatology, vol. 147, no. 5, pp. 859–868, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. I. Rogatsky, J. C. Wang, M. K. Derynck et al., “Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 13845–13850, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Schackert, H. C. Korting, and M. Schäfer-Korting, “Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo: characterisation of drugs with an increased benefit-risk ratio,” BioDrugs, vol. 13, no. 4, pp. 267–277, 2000. View at Scopus
  77. N. Radoja, M. Komine, S. H. Jho, M. Blumenberg, and M. Tomic-Canic, “Novel mechanism of steroid action in skin through glucocorticoid receptor monomers,” Molecular and Cellular Biology, vol. 20, no. 12, pp. 4328–4339, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Arenas, G. Moreno-Coutiño, L. Vera, and O. Welsh, “Tinea incognito,” Clinics in Dermatology, vol. 28, no. 2, pp. 137–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. I. H. Song, R. Gold, R. H. Straub, G. R. Burmester, and F. Buttgereit, “New glucocorticoids on the horizon: repress, don't activate!,” Journal of Rheumatology, vol. 32, no. 7, pp. 1199–1207, 2005. View at Scopus
  80. R. De Cid, E. Riveira-Munoz, P. L. J. M. Zeeuwen et al., “Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis,” Nature Genetics, vol. 41, no. 2, pp. 211–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. J. D. Bos and M. M. H. M. Meinardi, “The 500 Dalton rule for the skin penetration of chemical compounds and drugs,” Experimental Dermatology, vol. 9, no. 3, pp. 165–169, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Ishiko, T. Yokoyama, A. Tanikawa, M. Amagai, and K. Nagao, “A case of generalized pustular psoriasis treated with topical tacrolimus,” Archives of Dermatology, vol. 139, no. 9, p. 1219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. I. M. Zonnevdd, A. Rubins, S. Jablonska et al., “Topical tacrolimus is not effective in chronic plaque psoriasis: a pilot study,” Archives of Dermatology, vol. 134, no. 9, pp. 1101–1102, 1998. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Lebwohl, A. K. Freeman, M. S. Chapman, S. R. Feldman, J. E. Hartle, and A. Henning, “Tacrolimus ointment is effective for facial and intertriginous psoriasis,” Journal of the American Academy of Dermatology, vol. 51, no. 5, pp. 723–730, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. C. L. Carroll, J. Clarke, F. Camacho, R. Balkrishnan, and S. R. Feldman, “Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment,” Archives of Dermatology, vol. 141, no. 1, pp. 43–46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Remitz, S. Reitamo, P. Erkko, H. Granlund, and A. I. Lauerma, “Tacrolimus ointment improves psoriasis in a microplaque assay,” British Journal of Dermatology, vol. 141, no. 1, pp. 103–107, 1999. View at Publisher · View at Google Scholar · View at Scopus
  87. M. B. Brown, G. P. Martin, S. A. Jones, and F. K. Akomeah, “Dermal and transdermal drug delivery systems: current and future prospects,” Drug Delivery, vol. 13, no. 3, pp. 175–187, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. K. M. Huttunen, N. Mähönen, H. Raunio, and J. Rautio, “Cytochrome P450-activated prodrugs: targeted drug delivery,” Current Medicinal Chemistry, vol. 15, no. 23, pp. 2346–2365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. P. C. van de Kerkhof, J. Barker, C. E. Griffiths, et al., “Psoriasis: consensus on topical therapies,” Journal of the European Academy of Dermatology and Venereology, vol. 22, no. 7, pp. 859–870, 2008.
  90. L. Warino, R. Balkrishnan, and S. R. Feldman, “Clobetasol propionate for psoriasis: are ointments really more potent?” Journal of Drugs in Dermatology, vol. 5, no. 6, pp. 527–532, 2006. View at Scopus
  91. G. B. E. Jemec, C. Ganslandt, J. P. Ortonne et al., “A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial,” Journal of the American Academy of Dermatology, vol. 59, no. 3, pp. 455–463, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. C. C. Long and A. Y. Finlay, “The finger-tip unit—a new practical measure,” Clinical and Experimental Dermatology, vol. 16, no. 6, pp. 444–447, 1991. View at Scopus
  93. K. Kragballe, “Management of difficult to treat locations of psoriasis: scalp, face, flexures, palm/soles and nails,” Current Problems in Dermatology, vol. 38, pp. 160–171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. L. Stein, “Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis,” Journal of the American Academy of Dermatology, vol. 53, no. 1, Supplement 1, pp. S39–S49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. C. E. M. Griffiths, A. Y. Finlay, C. J. Fleming, J. N. W. N. Barker, F. Mizzi, and S. Arsonnaud, “A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis,” Journal of Dermatological Treatment, vol. 17, no. 2, pp. 90–95, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Beutner, A. Chakrabarty, S. Lemke, and K. Yu, “An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis,” Journal of Drugs in Dermatology, vol. 5, no. 4, pp. 357–360, 2006. View at Scopus
  97. B. Patel, S. Siskin, R. Krazmien, and M. Lebwohl, “Compatibility of calcipotriene with other topical medications,” Journal of the American Academy of Dermatology, vol. 38, no. 6, Part 1, pp. 1010–1011, 1998. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Lebwohl, S. B. Siskin, W. Epinette et al., “A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis,” Journal of the American Academy of Dermatology, vol. 35, no. 2, Part 1, pp. 268–269, 1996. View at Scopus
  99. R. M. Lavker, K. Kaidbey, and J. J. Leyden, “Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid,” Journal of the American Academy of Dermatology, vol. 26, no. 4, pp. 535–544, 1992. View at Scopus
  100. S. Morimoto and Y. Kumahara, “A patient with psoriasis cured by 1α-hydroxyvitamin D3,” Medical Journal of Osaka University, vol. 35, no. 3-4, pp. 51–54, 1985. View at Scopus
  101. E. Vakirlis, A. Kastanis, and D. Ioannides, “Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris,” Therapeutics and Clinical Risk Management, vol. 4, no. 1, pp. 141–148, 2008. View at Scopus
  102. J. L. O'Neill and S. R. Feldman, “Vitamin D analogue-based therapies for psoriasis,” Drugs of Today, vol. 46, no. 5, pp. 351–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. L. Kowalzick, “Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis,” British Journal of Dermatology, vol. 144, Supplement 58, pp. 21–25, 2001. View at Scopus
  104. L. Simonsen, G. Høy, E. Didriksen, J. Persson, N. Melchior, and J. Hansen, “Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle,” Drug Development and Industrial Pharmacy, vol. 30, no. 10, pp. 1095–1102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Traulsen and B. J. Hughes-Formella, “The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment,” Dermatology, vol. 207, no. 2, pp. 166–172, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. P. C. M. Van De Kerkhof, N. Wasel, K. Kragballe, F. Cambazard, and S. Murray, “A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity,” Dermatology, vol. 210, no. 4, pp. 294–299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. C. Buckley, V. Hoffmann, J. Shapiro, S. Saari, F. Cambazard, and M. Milsgaard, “Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study,” Dermatology, vol. 217, no. 2, pp. 107–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Lebwohl, “The role of salicylic acid in the treatment of psoriasis,” International Journal of Dermatology, vol. 38, no. 1, pp. 16–24, 1999. View at Publisher · View at Google Scholar · View at Scopus
  109. R. A. S. Chandraratna, “Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis,” Journal of the American Academy of Dermatology, vol. 37, no. 2, Part 3, pp. S12–S17, 1997. View at Publisher · View at Google Scholar · View at Scopus
  110. K. Kaidbey, S. C. Kopper, J. Sefton, and J. R. Gibson, “A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy,” International Journal of Dermatology, vol. 40, no. 7, pp. 468–471, 2001. View at Publisher · View at Google Scholar · View at Scopus
  111. G. D. Weinstein, J. Y. M. Koo, G. G. Krueger et al., “Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks,” Journal of the American Academy of Dermatology, vol. 48, no. 5, pp. 760–767, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. J. Y. M. Koo and D. Martin, “Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. versus mometasone furoate cream b.i.d. in the treatment of plaque psoriasis,” International Journal of Dermatology, vol. 40, no. 3, pp. 210–212, 2001. View at Publisher · View at Google Scholar · View at Scopus
  113. J. Y. M. Koo, N. J. Lowe, D. A. Lew-Kaya et al., “Tazarotene plus UVB phototherapy in the treatment of psoriasis,” Journal of the American Academy of Dermatology, vol. 43, no. 5, Part 1, pp. 821–828, 2000. View at Scopus
  114. D. Hecker, J. Worsley, G. Yueh, and M. Lebwohl, “In vitro compatibility of tazarotene with other topical treatments of psoriasis,” Journal of the American Academy of Dermatology, vol. 42, no. 6, pp. 1008–1011, 2000. View at Publisher · View at Google Scholar · View at Scopus
  115. H. I. Katz, N. T. Hien, S. E. Prawer, J. C. Scott, and E. M. Grivna, “Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis,” Archives of Dermatology, vol. 123, no. 10, pp. 1308–1311, 1987. View at Scopus
  116. H. I. Katz, S. E. Prawer, R. S. Medansky, G. G. Krueger, J. J. Mooney, and M. L. C. R. Jones Samson, “Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen,” Dermatologica, vol. 183, no. 4, pp. 269–274, 1991. View at Scopus
  117. J. Y. Koo, “New developments in topical sequential therapy for psoriasis,” Skin therapy letter., vol. 10, no. 9, pp. 1–4, 2005. View at Scopus
  118. T. Afifi, G. de Gannes, C. Huang, and Y. Zhou, “Topical therapies for psoriasis: evidence-based review,” Canadian Family Physician, vol. 51, pp. 519–525, 2005. View at Scopus
  119. M. G. Lebwohl, D. L. Breneman, B. S. Goffe et al., “Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis,” Journal of the American Academy of Dermatology, vol. 39, no. 4, Part 1, pp. 590–596, 1998. View at Publisher · View at Google Scholar · View at Scopus
  120. C. Levin and H. I. Maibach, “Topical corticosteroid-induced adrenocortical insufficiency: clinical implications,” American Journal of Clinical Dermatology, vol. 3, no. 3, pp. 141–147, 2002. View at Scopus
  121. A. Du Vivier and R. B. Stoughton, “Tachyphylaxis to the action of topically applied corticosteroids,” Archives of Dermatology, vol. 111, no. 5, pp. 581–583, 1975. View at Publisher · View at Google Scholar · View at Scopus